Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.

Oncotarget · 2015 · PMC4791238 · PMID 26517518

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Reparixin alone showed a trend in reducing NFkB levels, while paclitaxel was uneffective.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.